newsfilter
← Latest News
Business Wire·

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation

COYA
  • Coya Therapeutics published preclinical results for COYA 303 in the International Journal of Molecular Sciences, demonstrating complementary immunomodulatory effects of combining low-dose IL-2 (LD-IL2) with a GLP-1 Receptor Agonist (GLP-1RA).
  • The study utilized a subacute low-dose lipopolysaccharide (LPS) mouse model to simulate neurodegenerative disease features, showing that the combination treatment initiated 24 hours after inflammation onset produced broader effects than either monotherapy.
  • GLP-1RA attenuated myeloid expansion and inflammatory transcriptional responses, while LD-IL2 increased regulatory T cell (Treg) numbers and transcripts associated with Treg stability.
  • Peripheral immune analysis revealed that the combination significantly reduced pro-inflammatory IL-6 and TNF expression while increasing anti-inflammatory ARG1 expression.
  • In cortical and hippocampal brain regions, the combination reduced pro-inflammatory IL-6 and IL-1β while increasing markers of anti-inflammatory M2 macrophages (CD163 and CD206).
  • Treg-associated transcripts including IL-2Ra, TGF-b1, and CTLA-4 were enhanced by the combination treatment relative to monotherapies.
  • Coya believes these findings support further evaluation of COYA 303 for Alzheimer's disease, ALS, FTD, and other complex neurodegenerative indications driven by inflammation.
  • The company plans to pursue non-dilutive funding avenues and potential partnerships to advance the COYA 303 program.
  • The study was conducted by researchers at the Houston Methodist Neurological Institute and funded by Coya through a sponsored research agreement.